The current manuscript is the second update of the original Practical Guide, published in
2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of …

Background: Stroke reduction with direct oral anticoagulants (DOACs) in atrial fibrillation
(AF) is dependent on adherence and persistence in the real-world setting. Individual study …

Abstract The Canadian Cardiovascular Society (CCS) atrial fibrillation (AF) guidelines
program was developed to aid clinicians in the management of these complex patients, as …

Atrial fibrillation is found in a third of all ischaemic strokes, even more after post-stroke atrial
fibrillation monitoring. Data from stroke registries show that both unknown and untreated or …

Background In comparison to warfarin, non–vitamin K antagonist oral anticoagulants (NOAC
s) have the advantages of ease of dosing, fewer drug interactions, and lack of need for …

Importance Atrial fibrillation (AF) is associated with an increase in mortality and morbidity,
with a substantial increase in stroke and systemic thromboembolism. Strokes related to AF …

Antithrombotic drugs, which include antiplatelet and anticoagulant therapies, prevent and
treat many cardiovascular disorders and, as such, are some of the most commonly …

Abstract Background The EURObservational Research Programme-Atrial Fibrillation
General Registry Pilot Phase (EORP-AF Pilot) provides systematic collection of …

Background A growing body of evidence suggests that atrial fibrillation (AF) is associated
with myocardial infarction (MI). However, incidence and management of MI in AF is still …

The choice of oral anticoagulant (OAC) for patients with atrial fibrillation (AF) may be
influenced by individual clinical features or by patterns of risk factors and comorbidities. We …